TrialNature aging2021

ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease.

Petr Novak et al.PubMed ↗Publisher ↗

No numbers read from the abstract.